Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLGA: Durvalumab + Tremelimumab + Enfortumab Vedotin in Muscle Invasive Bladder Cancer
NCT04960709Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 25
01
Overview
A Phase 3 trial of durvalumab in muscle-invasive bladder cancer (MIBC), sponsored by AstraZeneca. Started Aug 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04960709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960709.